Capecitabine: A novel, orally administered, tumour-activated treatment for breast cancer

Journal of Oncology Pharmacy Practice

Volumn 8, Issue 1, 2002, Pages 1-17

  Summerhayes, Maxwell ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Capecitabine; Chemotherapy; Fluoropyrimidines

Indexed keywords

4 N ACETYLDINALINE; ALLOPURINOL; ALUMINUM MAGNESIUM HYDROXIDE; ANTHRACYCLINE; CAPECITABINE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXIFLURIDINE; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PHENYTOIN; PRODRUG; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; TIPIFARNIB; TRASTUZUMAB; WARFARIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DEHYDRATION; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVATION; DRUG INFORMATION; DRUG POTENTIATION; DRUG QUALITY; DRUG RESPONSE; DRUG SELECTIVITY; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; METASTASIS; MOUSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SOLID TUMOR; STOMATITIS; SYMPTOMATOLOGY; TREATMENT FAILURE; VERTIGO; VOMITING;

EID: 0036060550     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155202jp086oa     Document Type: Article

References (79)

1. Cancer research campaign factsheet 6.1. Breast cancer - UK
2. ONS monitor MBI 96/1 registration of cancer diagnosed in 1991, England and Wales
3. Breast cancer
4. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the multiple outcomes of raloxifene evaluation (MORE) trial
5. Is tamoxifen effective in prevention of breast cancer?
6. Report of the International Workshop on Screening for Breast Cancer
7. Polychemotherapy for early breast cancer: An overview of the randomised trials
8. Randomized trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy
9. Paclitaxel versus doxorubicin as first-line single agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over
10. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
11. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
12. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - A phase II study
13. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
14. Phase I-II trial of long term infusion (LTFUI) in the palliative therapy of metastatic breast cancer (MBC)
15. 'Xeloda' (capecitabine) product monograph
16. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
17. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
18. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
19. Tumor selectivity of Xeloda™ in colorectal cancer patients
20. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients
21. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
22. Role of thymidine phosphorylase for predicting the prognosis and therapeutic effects of 5′-deoxy-5-fluorouridine, an intermediate form of capecitabine, in early breast cancer patients; findings from a randomized controlled trial
23. Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors
24. Synergistic efficacy of Xeloda™ (capecitabine), a new oral tumor-activated fluoropyrimidine carbamate in combination with taxanes and with 2′-deoxy-2′ methylidenecytidine (DMDC)
25. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
26. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxyfluridine by cyclophosphamide in mammary tumour models
27. A phase I and pharmacological study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
28. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumours
29. A phase I study of capecitabine in combination with oral leucovorin in patients with advanced and/or metastatic solid cancer
30. A phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies
31. A randomised phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer
32. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomised phase II study
33. Raltitrexed and the treatment of advanced colorectal cancer
34. Improved therapeutic index with lower dose capecitabine in metastatic breast cancer (MBC) patients (Pts)
35. A multicenter phase II trial of Xeloda™ (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC)
36. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
37. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer
38. Capecitabine (XELODA) as treatment after failure to taxanes for metastatic breast cancer
39. A multicenter phase II trial of Xelodao™ (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer
40. Capecitabine: A new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter phase II trial
41. Capecitabine (C) in metastatic breast cancer (MBC) post-marketing surveillance of multiple outcomes in a universal health care system
42. Oral capecitabine is an active and well tolerated primary palliative treatment in patients with metastatic breast cancer who progress after high dose chemotherapy and autologous stem cell support
43. A phase II study of capecitabine in patients, who relapsed after high dose chemotherapy followed by peripheral blood stem cell transplantation for metastatic breast cancer
44. A phase II study of Xeloda™ (Capecitabine) in patients with advanced/metastatic breast carcinoma - The cooperative study group of capecitabine for breast carcinoma
45. A phase II study of capecitabine in elderly patients with advanced breast cancer
46. Dose finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated advanced breast cancer patients
47. TEX (Taxotere, Epirubicin and Xeloda) regimen as first line chemotherapy in advanced breast cancer. A multi-center phase II study
48. A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC)
49. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC)
50. A randomized phase II study of Xeloda™ (capecitabine) vs. CMF as first line chemotherapy of breast cancer in women aged 55 or over
51. A randomised phase II study of Xeloda™ (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy
52. Results of a large phase III trial of Xeloda®/Taxotere® combination therapy vs. Taxotere monotherapy in metastatic breast cancer (MBC) patients
53. Capecitabine as first-line treatment for metastatic colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
54. Characterizing hand-foot syndrome (HFS) caused by capecitabine
55. Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine
56. Xeloda. Summary of product characteristics
57. Phase I study of capecitabine in combination with a weekly schedule of irinotecan (CPT-11) as first-line chemotherapy in metastatic colorectal cancer
58. Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC)
59. A phase I trial of capecitabine (CAPE) and oxaliplatin (OHP)
60. Phase I study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumours
61. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial
62. Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumours
63. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
64. Xeloda™ (capecitabine) tablets
65. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
66. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
67. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies
68. 14C-labelled drug
69. Hepatic dysfunction due to liver metastases does not affect the bioactivation of Xeloda™
70. Effects of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
71. Guidance on the use of taxanes in breast cancer
72. Patient preference for oral versus intravenous palliative chemotherapy
73. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
74. A matrix-designed phase 1 dose-finding and pharmacokinetic study of the combination of Xeloda™ plus Taxotere™
75. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
76. Preliminary results of a phase I/II study of weekly docetaxel (Taxotere®) combined with intermittent capecitabine (Xeloda®) for patients with anthracycline pre-treated metastatic breast cancer
77. Phase I study of vinorelbine (V) and capecitabine (C) in advanced breast cancer (ABC)
78. Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer
79. An EORTC-IDBBC phase I study of cyclophosphamide (C) and epirubicin (E) in combination with capecitabine (X) (CEX) as primary treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC)